Fund · iShares U.S. Pharmaceuticals ETF · measured from SEC filings
IHE holdings
IHE reports 58 holdings and behaves like 8.7 equally weighted ones, computed from its SEC Form N-PORT filing for 2026-06-30. The fact sheet publishes the first number; this page computes the second, and traces it across 28 quarters of filings.
Measured concentration
as of 2026-06-30Read this figure with the following in mind
6.2% of net assets is securities-lending cash collateral, excluded from the figure; counted as filed the fund would read 8.4
The figure below is what the filing says, published unchanged. What it may not do is sit beside a plain long-only fund and be read as the same quantity. How comparability is decided.
Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 6 issuer countries.
What stands out
as of 2026-06-30IHE's largest investment is Johnson Johnson at 22.44% of net assets. ELI Lilly Co and Merck Co Inc follow; the three together are 49.24%. Ten companies are 76.11% of the fund; the other 48 share the rest. Among the 721 equity funds measured here, IHE behaves like 8.7 holdings against a median of 42.4 — 4.8 times more concentrated than the median. Across 28 quarterly filings IHE has held roughly steady since 2019-09-30 (8.6 then, 8.7 now). Between the 2026-03-31 and 2026-06-30 filings 3 positions were added and 2 dropped; 6.6% of the weight moved.
Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.
Every filing since 2019
28Between 2019-09-30 and 2026-06-30, IHE went from behaving like 8.6 equally weighted positions to 8.7 — 1% more, while its top ten went from 79.18% to 76.11% of net assets. Read across the funds on the concentration-over-time table.
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2026-06-30 | 58 | 8.7 | 76.11% | 22.44% |
| 2026-03-31 | 57 | 8.8 | 78.27% | 23.03% |
| 2025-12-31 | 56 | 8.3 | 77.73% | 23.76% |
| 2025-09-30 | 45 | 8.4 | 77.95% | 23.16% |
| 2025-06-30 | 38 | 8.4 | 79.01% | 22.65% |
| 2025-03-31 | 39 | 8.5 | 79.32% | 22.47% |
| 2024-12-31 | 43 | 7.8 | 80.51% | 23.75% |
| 2024-09-30 | 39 | 8.8 | 77.96% | 22.09% |
Earlier filings (20 more, back to 2019-09-30)
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2024-06-30 | 38 | 8.1 | 79.75% | 23.55% |
| 2024-03-31 | 36 | 8.5 | 78.74% | 22.35% |
| 2023-12-31 | 35 | 9.1 | 76.89% | 21.5% |
| 2023-09-30 | 35 | 7.9 | 81.23% | 23.65% |
| 2023-06-30 | 42 | 8.1 | 78.36% | 23.53% |
| 2023-03-31 | 43 | 9.2 | 77.71% | 22.85% |
| 2022-12-31 | 44 | 9.7 | 75.03% | 22.42% |
| 2022-09-30 | 43 | 9.2 | 77.05% | 23.52% |
| 2022-06-30 | 43 | 8.8 | 78.51% | 22.86% |
| 2022-03-31 | 47 | 8.8 | 79.03% | 22.52% |
| 2021-12-31 | 47 | 8.2 | 80.91% | 23.46% |
| 2021-09-30 | 48 | 9.5 | 77.01% | 22.33% |
| 2021-06-30 | 49 | 9.8 | 76.7% | 22.44% |
| 2021-03-31 | 47 | 9.6 | 77.32% | 23.11% |
| 2020-12-31 | 45 | 9.8 | 77.02% | 22.7% |
| 2020-09-30 | 49 | 9.5 | 75.9% | 22.35% |
| 2020-06-30 | 45 | 9.9 | 75.68% | 21.73% |
| 2020-03-31 | 46 | 10.6 | 73.93% | 20.16% |
| 2019-12-31 | 47 | 9.5 | 75.71% | 22.25% |
| 2019-09-30 | 47 | 8.6 | 79.18% | 22.69% |
One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.
As filed, collateral included
6.24% collateralIHE's filing lists 59 positions including 6.24% of net assets in securities-lending cash collateral. Counted as filed the fund reads 8.4 effective holdings with a top ten of 79.55%; on its own investments — the figure above — it reads 8.7 with a top ten of 76.11%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.
Largest positions, as filed
as of 2026-06-30The 15 largest of 58 positions in IHE's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: IHE.csv.gz.
| # | Position | Weight | Cumulative |
|---|---|---|---|
| 1 | JOHNSON & JOHNSON | 22.44% | 22.4% |
| 2 | ELI LILLY AND COMPANY | 22.25% | 44.7% |
| 3 | MERCK & CO., INC. | 4.55% | 49.2% |
| 4 | BRISTOL-MYERS SQUIBB COMPANY | 4.37% | 53.6% |
| 5 | ROYALTY PHARMA PLC | 4.34% | 57.9% |
| 6 | VIATRIS INC. | 4.22% | 62.2% |
| 7 | PFIZER INC. | 3.96% | 66.1% |
| 8 | ZOETIS INC. | 3.73% | 69.9% |
| 9 | JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | 3.45% | 73.3% |
| 10 | ELANCO ANIMAL HEALTH INCORPORATED | 2.81% | 76.1% |
| 11 | AXSOME THERAPEUTICS, INC. | 2.42% | 78.5% |
| 12 | CORCEPT THERAPEUTICS INCORPORATED | 1.90% | 80.4% |
| 13 | LIGAND PHARMACEUTICALS INCORPORATED | 1.45% | 81.9% |
| 14 | Definium Therapeutics Inc | 1.39% | 83.3% |
| 15 | Liquidia Corp | 1.28% | 84.5% |
By country of issuer
as of 2026-06-30Share of IHE's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.
| Country | Share |
|---|---|
| United States | 90.15% |
| United Kingdom | 4.34% |
| Ireland° | 3.78% |
| Canada | 1.39% |
| Singapore | 0.20% |
| Cayman Islands° | 0.15% |
Returns the fund reported
2019-07 – 2026-06Monthly total returns from Item B.5 of IHE's own filings, 84 months on record. Not computed here and not from a price feed.
Cross-checked against a series computed separately from prices: median difference 0.06 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: IHE.json · all funds.
Who borrows IHE's shares
2026-06-30The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-06-30, $71m was out to 16 borrowers, 6.21% of net assets. The largest, JP MORGAN SECURITIES LLC, held 29.5% of it.
| Borrower | On loan | Share of the loan |
|---|---|---|
| JP MORGAN SECURITIES LLC | $21m | 29.5% |
| National Financial Services LLC | $10m | 14.6% |
| BofA Securities, Inc. | $10m | 13.5% |
| GOLDMAN SACHS INTERNATIONAL | $9m | 12.0% |
| BNP PARIBAS SECURITIES CORP | $4m | 6.1% |
Cash collateral reported against the loan: 6.24% of net assets, 100.4% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter IHE has filed, with each borrower: IHE.json · all funds.
Since the previous filing
2026-03-31 → 2026-06-3057 positions became 58: 3 added (0.8% of the fund at the later date), 2 dropped (1.3% at the earlier date). Half the sum of all weight changes, a turnover proxy: 6.6%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of IHE compared this way, as a feed: changes.xml · all funds: filings received.
| Largest increases | 2026-03-31 | 2026-06-30 | Largest decreases | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|
| ELI LILLY AND COMPANY | 21.06% | 22.25% | ZOETIS INC. | 4.52% | 3.73% |
| Definium Therapeutics Inc | 0.52% | 1.39% | PFIZER INC. | 4.71% | 3.97% |
| CORCEPT THERAPEUTICS INCORPORATED | 1.05% | 1.90% | JOHNSON & JOHNSON | 23.03% | 22.44% |
| Liquidia Corp | 0.72% | 1.28% | ELANCO ANIMAL HEALTH INCORPORATED | 3.32% | 2.81% |
| AXSOME THERAPEUTICS, INC. | 2.00% | 2.42% | ROYALTY PHARMA PLC | 4.70% | 4.34% |
| ORGANON & CO. | 0.44% | 0.81% | PRESTIGE CONSUMER HEALTHCARE INC. | 0.78% | 0.51% |
New: Veradermics Inc (0.56%), AtaiBeckley Inc (0.23%), XAV HEALTH CARE SEP26 (0.00%). Gone: Terns Pharmaceuticals Inc (1.27%), LENZ Therapeutics Inc (0.06%).
Asset categories and pricing
as of 2026-06-3094.06% equity, 5.94% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.
Derivative exposure and counterparties
as of 2026-06-30A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $1.14B. Notional of an interest-rate or currency swap is not equity exposure.
Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).
Neighbours by effective holdings, equity funds
10Every measured equity fund lined up by how many holdings it behaves like; these sit either side of IHE (8.7). Same filings, same arithmetic. Position in this list says nothing about which fund is better.
| Fund | Reports | Behaves like | Top ten | As of |
|---|---|---|---|---|
| EWY iShares MSCI South Korea ETF | 84 | 6.3 | 69.83% | 2026-05-31 |
| ELM Elm Market Navigator ETF | 18 | 6.7 | 90.37% | 2026-06-30 |
| XLSR State Street(R) US Sector Rotation ETF | 29 | 7.2 | 88.52% | 2026-06-30 |
| EPU iShares MSCI Peru and Global Exposure ETF | 34 | 8 | 73.44% | 2026-05-31 |
| EWS iShares MSCI Singapore ETF | 20 | 8.2 | 80.68% | 2026-05-31 |
| AMLP Alerian MLP ETF | 14 | 9.6 | 93.72% | 2026-05-31 |
| FLKR Franklin FTSE South Korea ETF | 159 | 9.7 | 67.9% | 2026-06-30 |
| PSFF Pacer Swan SOS Fund of Funds ETF | 13 | 9.7 | 92.19% | 2026-07-31 |
| XLY State Street(R) Consumer Discretionary Select Sector SPDR(R) ETF | 50 | 9.8 | 69.18% | 2026-06-30 |
| DRSK Aptus Defined Risk ETF | 23 | 9.8 | 97.18% | 2026-07-31 |
Essays that examine IHE
0Mentions are detected across the full text of every article, so an appearance may be a passing comparison rather than the subject. Nothing here is a recommendation to buy or sell — see the disclaimer.